The launch simply started with the PR on Dec 22nd. There is much more to a 'launch' than just the initial PR. More to come for sure. They can't market an unregulated diagnostic like an FDA diagnostic. They can sell it through business development activities and use marketing materials to make that happen. That's why we don't see marketing activity. That should change slightly with CLIA but I am not sure of the rules with CLIA for marketing. We are sure to see better numbers. I think they will present univariate this week but I might be wrong. I think the multivariate would come with CLIA certification. There is a ton of info about to come our way. LP002, CLIA submission and approval, Lympro orders, Lympro globally?, ICON relationship, other player getting involved with Lympro?, diagnostic acquisition - that's just the diagnostic division. Games still going on with the share price but volume should temper that soon.